Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,480
-160 (-1.02%)
At close: Dec 5, 2025
4.81%
Market Cap 1.18T
Revenue (ttm) 1.20T
Net Income (ttm) -116.55B
Shares Out 75.96M
EPS (ttm) -1,880.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 586,178
Average Volume 648,713
Open 15,560
Previous Close 15,640
Day's Range 15,050 - 15,710
52-Week Range 9,260 - 16,020
Beta 0.38
RSI 71.83
Earnings Date Nov 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 278
Stock Exchange KOSDAQ
Ticker Symbol 085660
Full Company Profile

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.

Financial Statements

News

There is no news available yet.